Yesterday, Sept. 14, 2015, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $45.99 to $17,514,351.66.

Highlighted Stocks Traded by Insiders:

Spirit AeroSystems Holdings (SPR) - FREE Research Report

Johnson Robert D, who is Director at Spirit AeroSystems Holdings, sold 1,500 shares at $51.77 on Sept. 14, 2015. Following this transaction, the Director owned 15,100 shares meaning that the stake was reduced by 9.04% with the 1,500-share transaction.

The shares most recently traded at $50.69, down $1.08, or 2.13% since the insider transaction. Historical insider transactions for Spirit AeroSystems Holdings go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 35,255

The average volume for Spirit AeroSystems Holdings has been 1.0 million shares per day over the past 30 days. Spirit AeroSystems Holdings has a market cap of $7.2 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 17.89% year-to-date as of the close of trading on Monday.

Spirit AeroSystems Holdings, Inc., through its subsidiaries, operates as a non-original equipment manufacturer (OEM) that designs, engineers, and manufactures large commercial aircraft structures worldwide. The company has a P/E ratio of 17.8. Currently, there are 9 analysts who rate Spirit AeroSystems Holdings a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPR - FREE

TheStreet Quant Ratings

rates Spirit AeroSystems Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Spirit AeroSystems Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

FLIR Systems (FLIR) - FREE Research Report

Frank Jeffrey, who is Vice President, Global Product at FLIR Systems, sold 680 shares at $28.47 on Sept. 14, 2015. Following this transaction, the Vice President, Global Product owned 29,504 shares meaning that the stake was reduced by 2.25% with the 680-share transaction.

The shares most recently traded at $28.35, down $0.12, or 0.42% since the insider transaction. Historical insider transactions for FLIR Systems go as follows:

  • 4-Week # shares sold: 49,992
  • 12-Week # shares sold: 49,992
  • 24-Week # shares sold: 94,148

The average volume for FLIR Systems has been 776,100 shares per day over the past 30 days. FLIR Systems has a market cap of $4.0 billion and is part of the technology sector and electronics industry. Shares are down 12.7% year-to-date as of the close of trading on Monday.

FLIR Systems, Inc. designs, manufactures, and markets thermal imaging, visible-light imaging systems, locater systems, measurement and diagnostic systems, and threat-detection solutions worldwide. The stock currently has a dividend yield of 1.55%. The company has a P/E ratio of 18.1. Currently, there are 3 analysts who rate FLIR Systems a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLIR - FREE

TheStreet Quant Ratings

rates FLIR Systems as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

FLIR Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Psychemedics (PMD) - FREE Research Report

Kubacki Raymond C Jr, who is Chairman, CEO & President at Psychemedics, bought 2,000 shares at $10.12 on Sept. 14, 2015. Following this transaction, the Chairman, CEO & President owned 185,647 shares meaning that the stake was boosted by 1.09% with the 2,000-share transaction.

Lerner Neil, who is VP - Finance at Psychemedics, bought 3,000 shares at $10.32 on Sept. 14, 2015. Following this transaction, the VP - Finance owned 30,051 shares meaning that the stake was boosted by 11.09% with the 3,000-share transaction.

The shares most recently traded at $10.20, down $0.12, or 1.18% since the insider transaction. Historical insider transactions for Psychemedics go as follows:

  • 4-Week # shares sold: 2,837
  • 12-Week # shares sold: 2,837
  • 24-Week # shares sold: 2,837

The average volume for Psychemedics has been 16,500 shares per day over the past 30 days. Psychemedics has a market cap of $54.2 million and is part of the health care sector and health services industry. Shares are down 33.8% year-to-date as of the close of trading on Monday.

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The stock currently has a dividend yield of 6%. The company has a P/E ratio of 25.0. Currently, there are no analysts who rate Psychemedics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PMD - FREE

TheStreet Quant Ratings

rates Psychemedics as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income. Get the full

Psychemedics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.